[Regression of biochemical changes in heart muscle hypertrophy].
Reduction in arterial blood pressure caused by ACE inhibitors, calcium antagonists and beta-blockers leads to regression of heart muscle hypertrophy. However, this regression may also occur in the absence of a significant reduction in blood pressure (alpha-Methyldopa), whereas no decrease in heart muscle mass may be observed in the presence of pronounced decreases in blood pressure (hydralazine, minoxidil, diuretics). In the present review, biochemical factors are analyzed that might be important in the regression of heart muscle hypertrophy. It will be seen that angiotensin II and cardiac catecholamines play important roles in modifying the influence of various drugs on regression of heart muscle hypertrophy. Reductions in angiotensin II and cardiac catecholamines lead to decreases in cardiac mRNA contents and thus to a decrease in the myocardial protein synthesis. Changes in myocardial protein degradation do not contribute to the regression of heart muscle hypertrophy.
Zähringer
J
J
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D006332:Cardiomegaly / Q000188:drug therapy / Q000201:enzymology*; D003094:Collagen / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000201:enzymology; D007527:Isoenzymes / Q000378:metabolism; D008750:Methyldopa / Q000627:therapeutic use; D009124:Muscle Proteins / Q000378:metabolism; D009218:Myosins / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D007527:Isoenzymes; D009124:Muscle Proteins; D008750:Methyldopa; D003094:Collagen; D009218:Myosins
Biochemische Veränderungen bei Herzmuskelhypertrophieregression.